Abstract: OBJECTIVE To evaluate the clinical efficacy and safety of suhuang zhike capsule in the treatment of postinfectious cough. METHODS Retrieval of CNKI, Wanfang, VIP,CBM, Pubmed and The Cochrane Library on suhuang zhike capsule in the treatment of PIC clinical randomized controlled trials. Evaluate the risk of bias in the study of the method recommended by the Cochrane system. Used Review Manager 5.3 software to analysis. RESULTS A total of 9 studies were included in 741 patients. There was a higher risk of bias included in the study methodology majority. The result showed that:① The treatment group was better than the control group, the difference was statistically significant(OR=3.43, 95%CI(2.23, 5.29), P<0.000 01); ② On cough integration(SMD=-0.53, 95%CI(-0.92, -0.15), P=0.007), TCM syndrome(OR=2.64, 95%CI(1.32, 5.31), P=0.006), Suhuang Zhike capsules were also better than the control group, the differences were statistically significant. ③ There was significant difference between the two groups on cough disappearance time(MD=-3.04, 95%CI(-5.86, -0.22), P=0.03); But there was no significant difference between the two groups on cough onset time(SMD=-1.2, 95%CI(-2.65, 0.26), P=0.11). ④ The incidence of adverse reactions in the treatment group and the control group were not statistically significant(OR=0.91, 95%CI(0.31, 2.65), P=0.86). CONCLUSION Suhuang Zhike capsule treatment of PIC is effective, safe and reliable. The clinical practice has an alternative. But still need more large samples, high quality randomized controlled trials to be confirmed.